A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...